Home › Research › Health systems and care delivery
Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder
Sinem Perk, Ronald C. Wielage, Noll L. Campbell, Timothy M. Klein, Anthony J. Perkins, Linda M. Posta, Thomas E. Yuran, Robert W. Klein et al.. Journal of Managed Care & Specialty Pharmacy, 2016-08-31
Topic: Risk, prevention and care in population studies
Plain-language summary
Primary analysis calculated the impact of increasing the use of mirabegron from 4.5% to 5.3%, 7.1%, and 9.4% in years 1, 2, and 3, respectively, among oral pharmacological OAB treatments that included generic and branded antimuscarinics: oxybutynin, tolterodine, trospium, darifenacin, fesoterodine, and solifenacin. For a 1 million-member U.S. commercial payer plan, the total prescription costs increased, and the total medical costs decreased during the 3-year time horizon, yielding increases of $0.005, $0.016, and $0.031 from current per member per month (PMPM) costs and $0.90, $2.92, and $5.53 from current per treated member per month (PTMPM) costs, an average of less than 2% of current OAB treatment costs. For the Medicare Advantage plan, the resulting incremental PMPM costs were $0.010, $0.034, and $0.065, and the incremental PTMPM costs were $0.93, $3.04, and $5.76; all were less than 4% of the current cost. The secondary analysis estimated the budgetary effects of reducing the untreated population by 1% annually by initiating treatment with mirabegron. For a commercial payer, this resulted in PMPM cost increases of $0.156, $0.311, and $0.467 from the current value, while the incremental PTMPM cost increased by $6.17, $11.67, and $16.61. For the Medicare Advantage plan, the incremental increases in PMPM costs were $0.277, $0.553, and $0.830, and in PTMPM costs were $6.42, $12.15, and $17.29. Clinically, treating more OAB patients resulted in fewer OAB-related comorbidities from both health plan perspectives, since most events associated with nontreatment could be avoided. In the Medicare Advantage population of the secondary analysis, the total numbers of avoided events were predicted as 452 UTIs, 2,598 depression diagnoses, and 3,020 skin rashes during the time horizon of the model. Mirabegron addresses an unmet need for therapy for certain OAB patients, for whom antimuscarinics are not recommended because of a risk of cognitive impairment and who are intolerant to the anticholinergic AEs. Using mirabegron involves moderate additional economic cost to a commercial or Medicare Advantage health plan for which medical cost savings can offset a substantial part of increased pharmacy costs. DISCLOSURES: Funding for this study was provided by Astellas. Klein are employed by Medical Decision Modeling, a contract research company that was paid to perform the described outcomes research and build the model contained in this study. Campbell and Perkins are empl
What this study adds
Evidence grade: Moderate
This study estimated the budget impact of increasing use of mirabegron for overactive bladder. Reported effect size: 4.5% to 5.3%; 7.1%; 9.4%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Perk, S., Wielage, R. C., Campbell, N. L., Klein, T. M., Perkins, A. J., Posta, L. M., et al. (2016). Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. Journal of Managed Care & Specialty Pharmacy. https://doi.org/10.18553/jmcp.2016.22.9.1072
Vancouver
Perk S, Wielage RC, Campbell NL, Klein TM, Perkins AJ, Posta LM, et al. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder. Journal of Managed Care & Specialty Pharmacy. 2016. doi:10.18553/jmcp.2016.22.9.1072. PMID: 27579830.
BibTeX
@article{perk2016-27579830,
author = {Perk, Sinem and Wielage, Ronald C. and Campbell, Noll L. and Klein, Timothy M. and Perkins, Anthony J. and Posta, Linda M. and Yuran, Thomas E. and Klein, Robert W. and others},
title = {{Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder}},
journal = {Journal of Managed Care \& Specialty Pharmacy},
year = {2016},
doi = {10.18553/jmcp.2016.22.9.1072},
pmid = {27579830},
url = {https://doi.org/10.18553/jmcp.2016.22.9.1072}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Primary analysis calculated the impact of increasing the use of mirabegron from 4.5% to 5.3%, 7.1%, and 9.4% in years 1, 2, and 3, respectively, among oral pharmacological OAB treatments that included generic and branded antimuscarinics: oxybutynin, tolterodine, trospium, darifenacin, fesoterodine, and solifenacin.
- For a 1 million-member U.S. commercial payer plan, the total prescription costs increased, and the total medical costs decreased during the 3-year time horizon, yielding increases of $0.005, $0.016, and $0.031 from current per member per month (PMPM) costs and $0.90, $2.92, and $5.53 from current per treated member per month (PTMPM) costs, an average of less than 2% of current OAB treatment costs.
- For the Medicare Advantage plan, the resulting incremental PMPM costs were $0.010, $0.034, and $0.065, and the incremental PTMPM costs were $0.93, $3.04, and $5.76; all were less than 4% of the current cost.
- The secondary analysis estimated the budgetary effects of reducing the untreated population by 1% annually by initiating treatment with mirabegron.
- For a commercial payer, this resulted in PMPM cost increases of $0.156, $0.311, and $0.467 from the current value, while the incremental PTMPM cost increased by $6.17, $11.67, and $16.61.
Why it matters
This study estimated the budget impact of increasing use of mirabegron for overactive bladder. It concerns overactive bladder treatment costs, not Alzheimer's disease, so it has no implications for treating, curing or preventing dementia.
Study details
- Effect size4.5% to 5.3%; 7.1%; 9.4%
- Evidence strengthModerate
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Managed Care & Specialty Pharmacy) |
| Journal's citation record | 0 / 4 | Journal of Managed Care & Specialty Pharmacy: journal h-index 60 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 2 / 6 | Cited 2.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Daniel Ng: h-index 10 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Purdue University West Lafayette: institution h-index 983 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27579830) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.18553/jmcp.2016.22.9.1072
- PubMed: 27579830
- Original source →
- Free full text: Journal of Managed Care & Specialty Pharmacy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery from nearby years
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.